Literature DB >> 7752758

Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

N Almond1, K Kent, M Cranage, E Rud, B Clarke, E J Stott.   

Abstract

A vaccine against AIDS will probably have to protect against challenge both by viable virus-infected cells and by cell-free virus. Eight cynomolgus macaques infected with attenuated simian immunodeficiency virus (SIV) were challenged (four each) with cell-free and cell-associated SIV. All were protected, whereas eight controls were all infected after challenge. These findings show that live-attenuated vaccine can confer protection against SIV in macaques. Extrapolation to human beings will require extensive evaluation of the safety of attenuated retroviruses. Alternatively, the mechanism of this potent protection must be understood and reproduced by less hazardous means.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome--prevention and control; Animals, Laboratory; Clinical Research; Diseases; Hiv Infections; Research Methodology; Research Report; Vaccines; Viral Diseases

Mesh:

Substances:

Year:  1995        PMID: 7752758     DOI: 10.1016/s0140-6736(95)92540-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  70 in total

1.  Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge.

Authors:  D L Sodora; K E Sheridan; P A Marx; R I Connor
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  AIDS vaccine development: let a thousand flowers bloom.

Authors:  J S Oxford; M Addawe; R Lambkin
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

3.  Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

Authors:  Barbara L Shacklett; Karen E S Shaw; Lou A Adamson; David T Wilkens; Catherine A Cox; David C Montefiori; Murray B Gardner; Pierre Sonigo; Paul A Luciw
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

5.  Simian immunodeficiency virus SIVmac239Deltanef vaccination elicits different Tat28-35SL8-specific CD8+ T-cell clonotypes compared to a DNA prime/adenovirus type 5 boost regimen in rhesus macaques.

Authors:  Benjamin J Burwitz; Zachary Ende; Benjamin Sudolcan; Matthew R Reynolds; Justin M Greene; Benjamin N Bimber; Jorge R Almeida; Monica Kurniawan; Vanessa Venturi; Emma Gostick; Roger W Wiseman; Daniel C Douek; David A Price; David H O'Connor
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

6.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

8.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

9.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo.

Authors:  Justin M Greene; Jennifer J Lhost; Benjamin J Burwitz; Melisa L Budde; Caitlin E Macnair; Madelyn K Weiker; Emma Gostick; Thomas C Friedrich; Karl W Broman; David A Price; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.